Brain cancer vax looks promising in small trial

A small Phase I trial of an experimental dendritic cell based brain cancer vaccine advanced by ImmunoCellular Therapeutics (IMUC) has produced some unusually positive results. Only 16 patients suffering from glioblastoma multiforme--the most common of all brain cancers - were recruited for the study. But researchers report that 18 months after treatment began, almost half of the patients were still alive without any worsening of their disease. The 12-month disease-free survival from the time of...